The outcome of IHE initiatives is providing better information for developing health policy and best medical practices. IHE disseminates information in many ways. In addition to publications in peer-reviewed journals, IHE produces books and a variety of reports synthesizing information in a particular field.
Results for: Don Husereau
Combination therapy is the use of two or more therapies with the intention of improving patient health which are increasingly becoming more prevalent in the health system. Combination therapies can be produced by a single manufacturer but often the various components of the combination are produced by different companies which creates complexities in terms of pricing and reimbursement…
Pustular psoriasis is a rare form of psoriasis and a chronic disease, with patients experiencing diminished quality of life, reduced productivity, stigma, and shortened life expectancy from disease. Optimal management of pustular psoriasis requires access to healthcare providers with highly specialized knowledge. The rarity of the condition means some patients may receive inappropriate…
The purpose of this report is to provide a summary of current information and stakeholder perspectives regarding the current and future state of regenerative medicine (with a focus on stem cell-based research) in Canada and globally. Specifically, it assesses the strengths, potential areas for improvement, and opportunities for growth in the Canadian sector to ensure the future…
The Institute for Health Economics (IHE) conducted a roundtable on PF-ILD, in November 2021 and policy recommendations from the diverse stakeholder group provided some guidance on areas to focus on to improve the lives of those living with progressive fibrosing interstitial lung disease. Key actions identified at the roundtable included: increased surveillance for early identification…
This document describes the entry of new medical devices into the Canadian health system. It is intended to provide an accurate description of new medical device entry in Canada, and is intended to give patients, the public, private and public sector health system researchers, medical device companies, and private and public coverage bodies a general understanding of what regulatory,…
Objectives: Economic evaluations, although not formally used in purchasing decisions for medical devices in Canada, are still being conducted and published. The aim of this study was to examine the way that prices have been included in Canadian economic evaluations of medical devices.
Abstract: Canadian and US health systems have often been characterized as having vastly different approaches to the financing and delivery of healthcare, with Canada portrayed as more reliant on rationing based on costs. In this article, we examine the similarities and differences between the two countries, the evolution and current role of health economic evaluation, and…
This discussion paper has been produced in response to a request from CIHR Institute of Health Services and Policy Research (CIHR IHSPR). The discussion paper will provide guidance to those tasked with conducting an economic evaluation of complex health system interventions. The guidance will be an elaboration of existing National guidelines for economic evaluation, and serve as…
BACKGROUND: The use of a restrictive formulary, with placement determined through a drug-reimbursement decision-making process, is one approach to managing drug expenditures.
This report is an analysis of the theoretical basis for value-based pricing, relevant international developments, and areas for improvement within Canada’s current patented drug pricing system. This report intends to inform future policy research, advice, and Canadian drug policy discussions regarding the feasibility and implementation of value-based pricing approaches.
